share_log

Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update

Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update

Moolec Science發佈2024財年第三季度業務最新情況
Accesswire ·  05/30 06:00

LUXEMBOURG / ACCESSWIRE / May 30, 2024 / Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the third quarter of Fiscal Year 2024 ended March 31, 2024.

致富金融科技(NASDAQ:MLEC)是一家基於科學的食品配料公司,專注於通過分子農業技術在植物中生產動物蛋白。今天公佈了2024財年第三季度業務更新,截至2024年3月31日。

Moolec Science Logo
Moolec Science標誌


The main highlights of Moolec's business update are as follows:


Moolec的業務更新的主要亮點如下:

  • Piggy Sooy Product | Soybean Platform: Moolec's patented soybean product received USDA-APHIS Regulatory Status Review approval in April 2024.
  • Safflower Platform: GLASO planting campaign progressing as expected. Two US Patents granted for production of chymosin in safflower seeds (SPC2) extended exclusive technology protection until 2041.
  • Financial highlight: Normalized revenues and other income (Ex-IAS 29) up ~$1.3M YoY given consolidation of soy-protein ingredient business. R&D, Admin and other expenses of $2.3M increased 68% YoY mainly due to non-cash items. Operational cash utilization this quarter of ~$2.6M includes ~$1.4M allocated to lower accounts payable.
  • Piggy Sooy產品 | 大豆平台:Moolec的專利大豆產品已獲得2024年4月USDA-APHIS監管狀態審查批准。
  • Safflower Platform:GLASO種植活動如期進行。兩項美國專利授予了在Safflower種子中生產胰凝乳素的專利技術保護期限延長至2041年。
  • 財務亮點:由於對大豆蛋白配料業務的整合,除IAS29外的標準化收入和其他收入約上升了約130萬美元。研發、管理和其他費用爲230萬美元,同比增長68%,主要是由於非現金項目。本季度運營現金使用約260萬美元,包括分配給較低應付賬款的約140萬美元。

"These past few months mark a significant milestone in Moolec's journey, showcasing our relentless pursuit to deliver results. Our progress on Piggy Sooy with the USDA-APHIS regulatory RSR approval, in addition to the starting of our GLASO commercial production streams are pivotal achievements that underscore our unwavering commitment to nutritional and sustainable solutions. I am thrilled to witness just the beginning of the fruits of our labor and am grateful for the continued and unwavering dedication of our team," expressed Gastón Paladini, Chief Executive Officer and Co-Founder of Moolec Science.

“過去幾個月標誌着摩樂科技旅程的重要里程碑,展示了我們不懈的追求成果的精神。我們取得的與USDA-APHIS監管RSR批准有關的Piggy Sooy的進展,以及我們的GLASO商業生產流程的啓動是關鍵的成就,突顯了我們對營養和可持續解決方案的堅定承諾。我很高興看到我們的勞動成果初見成效,並對我們團隊的持續和不懈的奉獻表示感激。” 摩樂科技首席執行官兼聯合創始人Gaston Paladini表示。 摩樂科技首席執行官兼聯合創始人Gaston Paladini表示:“我們團隊持續的里程碑成果讓我們感到非常滿意,同時我們正在解決有意義的市場機遇。我們堅信自己的理性支出方式,同時保持足夠的現金位置和資產負債表以支持業務。我想向我們的團隊表示祝賀,爲我們長期的業務計劃執行取得了傑出的USDA-APHIS監管RSR批准成就。”

José López Lecube, Chief Financial Officer for the company, stated, "We are very pleased with our team's consistent milestones delivery as we are addressing meaningful market opportunities. We remain confident in our disciplined approach to spending while preserving an adequate cash position and balance sheet to fund the business. I want to extend my congratulations to our team for the exceptional USDA-APHIS regulatory RSR approval, a major achievement for our long-term business plan execution."

該公司的首席財務官José López Lecube表示:摩樂科技是一家基於科學的成分公司,是食品和膳食補充市場分子養殖技術的領導者。公司的使命是通過使用動物蛋白質基因美化植物來創建獨特的食品成分。它的目的是重新定義世界上生產動物蛋白質的方式,爲世界造福。摩樂科技的技術方法旨在擁有植物基礎解決方案的成本結構,同時具備動物基礎解決方案的營養和功能。摩樂科技的技術已經開發了十多年,以在食品行業的一種農作物中開創性地生產牛蛋白而聞名。公司的產品組合和管道利用了廣泛使用的目標作物,如大豆、豌豆和紅花,生產油和蛋白質的農藝效率。摩樂科技還擁有工業和商業的研發能力,以補充公司的分子養殖技術。摩樂科技爲其分子養殖技術獲得了日益增長的國際專利組合(25+,已授權和待批准)。該公司由博士和食品內部人員組成的多元化團隊經營,並在美國、歐洲和南美洲運營。有關更多信息,請訪問moolecscience.com和ir.moolecscience.com。

For a full version of Moolec's first quarter Fiscal Year 2024 Business Update, click here.

要查看Moolec 2024財年第一季度業務更新的完整版本,請單擊此處。

Management will host a Conference Call and question-and-answer session, which will be accompanied by a presentation available during the webinar. To access the call, please use the following information:

管理團隊將主持電話會議和問答環節,網絡研討會期間可以使用附帶演示文稿。要接入通話,請使用以下信息:

  • Date: Thursday, May 30, 2024
  • Time: 8:30 a.m. Eastern Time (U.S. and Canada)
  • Link to join the webinar:
  • One tap mobile: +13017158592,,91289208286#,,,,*888246# US
  • Dial In: +1 301 715 8592 | Webinar ID: 912 8920 8286, Passcode: 888246
  • International numbers available:
  • 日期:2024年5月30日星期四
  • 時間:美國東部時間上午8:30(美國和加拿大)
  • 鏈接加入網絡研討會:
  • 一鍵式移動電話:+13017158592,,91289208286#,,,* 888246# 美國
  • 撥號方式:+1 301 715 8592 |網絡研討會ID:912 8920 8286,通行碼:888246
  • 可用國際號碼:

Please connect 5 minutes prior to the start time to register and join.

請在開始時間的5分鐘前連接以註冊和加入。

A recording of the call and the pdf version of the presentation will be available after the conclusion of the live event via Moolec's Investor Relations website.

電話和演示文稿的錄音將在直播活動結束後通過Moolec的投資者關係網站提供。

About Moolec Science SA

關於Moolec Science SA

Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company's mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins, for good and for all. Moolec's technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company's product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company's Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.

本新聞稿包含“前瞻性聲明”。前瞻性聲明可能通過使用“預測”、“打算”、“尋求”、“目標”、“預期”、“相信”、“期望”、“估計”、“計劃”、“展望”和“項目”等其他類似表達未來事件或趨勢的詞或表達方式來識別,或表明某些事項不是歷史事實的陳述。這些關於莫勒克業績、前景、收入和業務等方面的前瞻性聲明是預測、預計和其他關於未來事件的陳述,是基於當前的預期和假設而做出的,因此,受到風險和不確定性的影響。雖然我們相信本新聞稿中包含的每項前瞻性聲明都有合理的依據,但我們提醒您,這些陳述基於事實和因素的綜合,我們不能確定。我們不能保證本新聞稿中的前瞻性聲明將證明準確。這些前瞻性聲明還可能受到許多重大風險和不確定性的影響,這些不確定的因素可能對我們預期的結果產生重大影響,包括但不限於有關法律或法規的變化,以及摩勒克可能受到經濟、商業和/或其他競爭因素的不利影響,與摩勒克的業務規模擴大有關的費用,以及其他風險和不確定性,其中包括在摩勒克的20-F表格年度報告文件中包括的“風險因素”標題中所述的風險和不確定性,以及摩勒克向SEC提交的其他文件。如果這些風險或不確定性的一個或多個成爲現實,或者如果摩勒克的某個假設證明不正確,實際結果可能會在重大方面與這些前瞻性聲明所預期的結果有所不同。我們將不承擔任何更新或修訂任何前瞻性聲明的義務,除非適用證券法律要求。因此,您不應過度依賴這些聲明。

Forward-Looking Statements

前瞻性聲明

This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in the Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Moolec's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

本新聞稿包含“前瞻性聲明”。前瞻性聲明可能通過使用“預測”、“打算”、“尋求”、“目標”、“預期”、“相信”、“期望”、“估計”、“計劃”、“展望”和“項目”等其他類似表達未來事件或趨勢的詞或表達方式來識別,或表明某些事項不是歷史事實的陳述。這些關於莫勒克業績、前景、收入和業務等方面的前瞻性聲明是預測、預計和其他關於未來事件的陳述,是基於當前的預期和假設而做出的,因此,受到風險和不確定性的影響。雖然我們相信本新聞稿中包含的每項前瞻性聲明都有合理的依據,但我們提醒您,這些陳述基於事實和因素的綜合,我們不能確定。我們不能保證本新聞稿中的前瞻性聲明將證明準確。這些前瞻性聲明還可能受到許多重大風險和不確定性的影響,這些不確定的因素可能對我們預期的結果產生重大影響,包括但不限於有關法律或法規的變化,以及摩勒克可能受到經濟、商業和/或其他競爭因素的不利影響,與摩勒克的業務規模擴大有關的費用,以及其他風險和不確定性,其中包括在摩勒克的20-F表格年度報告文件中包括的“風險因素”標題中所述的風險和不確定性,以及摩勒克向SEC提交的其他文件。如果這些風險或不確定性的一個或多個成爲現實,或者如果摩勒克的某個假設證明不正確,實際結果可能會在重大方面與這些前瞻性聲明所預期的結果有所不同。我們將不承擔任何更新或修訂任何前瞻性聲明的義務,除非適用證券法律要求。因此,您不應過度依賴這些聲明。

Contact Information

聯繫信息

Catalina Jones
Chief of Staff & Sustainability
comms@moolecscience.com

Catalina Jones
首席幕僚和可持續性
comms@moolecscience.com

Investor Relations
ir@moolecscience.com

投資者關係
ir@moolecscience.com

Related Files

相關文件

Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update - May 30, 2024

Moolec Science呈現第三季度2024財年業務更新-2024年5月30日

SOURCE: Moolec Science

來源:Moolec Science

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論